Second-line therapy of advanced ovarian cancer with GnRH analogs
International Journal of Gynecological Cancer, ISSN: 1048-891X, Vol: 14, Issue: 5, Page: 799-803
2004
- 22Citations
- 7Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations22
- Citation Indexes21
- 21
- CrossRef13
- Policy Citations1
- 1
- Captures7
- Readers7
Article Description
Balbi G, Piano LD, Cardone A, Cirelli G. Second-line therapy of advanced ovarian cancer with GnRH analogs. Int J Gynecol Cancer 2004; 14 :799—803. Ovarian cancer is still the first cause of death among female malignancies. The standard treatment adopted in ovarian cancer is a radical surgical treatment or cytoreduction, followed by six courses of platinum-based chemotherapy; second-line regimens are associated with severe side effects. GnRH analogs could represent an alternative therapeutical approach. The aim of our study was to evaluate the role of GnRH analogs in the management of platinum-resistant ovarian cancers. We enrolled 12 patients affected by advanced ovarian cancer, previously treated with six courses of platinum–paclitaxel. In second-line therapy, we used leuprolide on 1, 8, and 28 days of treatment. CA 125 levels were recorded for each patient. One case of clinical partial response was obtained (8.3%). Stable disease was diagnosed in three patients (25%). Progression was recorded in eight cases (66.7%). Progression-free survival was 6 months. The treatment was well tolerated by patients. The high tolerability and the results obtained with leuprolide versus platinum in second-line therapy might permit a better use of the analogs for advanced ovarian cancer.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1048891X24199343; http://dx.doi.org/10.1136/ijgc-00009577-200409000-00010; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=4544264455&origin=inward; http://dx.doi.org/10.1111/j.1048-891x.2004.014511.x; http://www.ncbi.nlm.nih.gov/pubmed/15361187; https://ijgc.bmj.com/lookup/doi/10.1111/j.1048-891X.2004.014511.x; http://doi.wiley.com/10.1111/j.1048-891X.2004.014511.x; https://linkinghub.elsevier.com/retrieve/pii/S1048891X24199343; https://dx.doi.org/10.1136/ijgc-00009577-200409000-00010; https://ijgc.bmj.com/content/14/5/799
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know